1 month Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High? Zacks
The mean of analysts’ price targets for EyePoint Pharmaceuticals (EYPT) points to a 175.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
X